Tuesday, February 09, 2010

Feedback| Helpdesk |Sign up| Login

 EDITORIAL
CLINICAL ESTABLISHMENT ACT
past editorials ...
SERVICES
PHARMA TENDERS & PROJECTS
Tenders&Enquiries
Pharma Projects
CORPORATE
Company Profiles
Corporate Results
Corporate X-ray
Pharmabiz Studies of Top Companies
Indian Cos Approved by Intl Regulatory Agencies
US FDA UPDATE
US FDA: ANDA - NEW
US FDA: Warnings
US FDA: Approved NMEs upto November 2008
US FDA: New Approvals
US approved Labs with Stem Cell Lines
EXPORT & IMPORT
Drug Export Procedures
Drug Registration Norms for Various Countries
Drug Units With WHO GMP Certification
Pharma Export Data
Import Reg. Update
PHARMA LAWS & DOCUMENTS
Notifications
Pharma Regulations
Patent Laws and Amendments
Patent Scan
Documents
New Drug Approvals
Notified Prices
List of banned FDCs w.e.f. 01.01.2002
List of formulations containing PPA
List of FDCs of Rifampicin + Isoniazid
LIST OF LABS & GOVT. BODIES
Govt Recognised In-House R&D Units
AICTE Boards & Committees
List of Indian CROs
List of CROs (International)
Govt & approved labs of India

SPECIAL FEATURES
Features
Business of PHARMA MARKETING

 INTERVIEW
'ISM has found foothold in several countries'
Dr T Thirunarayanan, secretary of CTMR

past interviews ...
  Clinical Trials

Avanir's pseudobulbar affect drug Zenvia meets endpoint in phase III study


Monday, August 17, 2009 16:00 IST
Aliso Viejo, California

Avanir Pharmaceuticals, Inc announced that the investigational drug Zenvia (dextromethorphan/quinidine) met its primary efficacy endpoint in the treatment of pseudobulbar affect (PBA) in the confirmatory phase-III STAR trial.


Read complete story ...
(You will need to login first to read this story.)

Post a Comment

E-mail this article!

Printer friendly!



 









FORTHCOMING EVENTS
International
Domestic

CHRONICLE PHARMABIZ SPECIALS
Forthcoming
Past



CORPORATE
Pharma Stocks
Executive Diary
Pharma People
Product Launches

PHARMA MART
Buyer's Postings
Flash Sales Offer
Used Equipment
Contract Manufacturing
Surplus Inventory


 

Copyright © Saffron Media Pvt. Ltd.
Designed & Maintained by Fast Cursor